A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients

NCT02589275 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

375

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Fibromyalgia

Interventions

DRUG: TNX-102 SL Tablet 2.8 mg

Sponsor

Tonix Pharmaceuticals, Inc.